Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dexamethasone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02605356 | Phase Ib/II | Radium Ra 223 dichloride Bortezomib Dexamethasone | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | Withdrawn | USA | ITA | ISR | GRC | ESP | DEU | CAN | BEL | AUS | 2 |
NCT02490878 | Phase II | Dexamethasone Prednisone Bevacizumab | Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases | Terminated | USA | CAN | 0 |
NCT02881086 | Phase III | Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | Active, not recruiting | DEU | 0 |
NCT02659800 | Phase I | Dexamethasone + NT-I7 Dexamethasone | Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas | Terminated | USA | 0 |
NCT02518113 | Phase Ib/II | Dexamethasone LY3039478 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | Completed | USA | ITA | ISR | FRA | DEU | 0 |
NCT03571321 | Phase I | Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Ruxolitinib Cyclophosphamide Dexamethasone Vincristine Sulfate Rituximab Doxorubicin | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT01459211 | Phase II | Dexamethasone Lenalidomide | Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) | Completed | GBR | 0 |
NCT02400242 | Phase I | Citarinostat Dexamethasone Pomalidomide | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | Terminated | USA | GRC | FRA | ESP | DEU | 0 |
NCT04037462 | Phase Ib/II | Dexamethasone | Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy | Terminated | USA | 0 |
NCT03259503 | Phase Ib/II | Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab | Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas | Active, not recruiting | USA | 0 |
NCT02576977 | Phase III | Pomalidomide Pembrolizumab Dexamethasone | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | Terminated | 0 | |
NCT03004287 | Phase II | Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | Active, not recruiting | USA | 0 |
NCT02420860 | Phase II | Famotidine Elotuzumab + Lenalidomide Diphenhydramine Dexamethasone | Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT) | Active, not recruiting | USA | 0 |
NCT01455389 | Phase Ib/II | Quaratusugene Ozeplasmid Erlotinib Diphenhydramine Dexamethasone | FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer | Terminated | USA | 0 |
NCT02464657 | Phase Ib/II | Dexamethasone Cytarabine + Idarubicin + Nivolumab | Nivolumab in Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT03418038 | Phase II | Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma | Recruiting | USA | 0 |
NCT03150693 | Phase III | Rituximab Doxorubicin Mercaptopurine Methotrexate Cyclophosphamide + Cytarabine Thioguanine Allopurinol Daunorubicin Dexamethasone Vincristine Sulfate Inotuzumab ozogamicin | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | Suspended | USA | CAN | 0 |
NCT02520115 | Phase I | Dexamethasone Valproic acid | Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | Completed | USA | 0 |
NCT02471911 | Phase I | Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | Completed | USA | 0 |
NCT02036502 | Phase I | Dexamethasone Lenalidomide + Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | Terminated | 0 | |
NCT02685826 | Phase I | Dexamethasone Durvalumab + Lenalidomide | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma | Completed | USA | NLD | ITA | FIN | ESP | DNK | DEU | CAN | 0 |
NCT02906332 | Phase II | Pembrolizumab Dexamethasone | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | Terminated | USA | 0 |
NCT02279394 | Phase II | Dexamethasone Elotuzumab + Lenalidomide | Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma | Completed | USA | 0 |
NCT01483690 | Phase Ib/II | Pegaspargase Methotrexate Dexamethasone Vincristine Sulfate Decitabine Mitoxantrone | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | Terminated | USA | AUS | 0 |
NCT01363817 | Phase I | Dexamethasone BMS-906024 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Completed | USA | FRA | DEU | 0 |
NCT02491411 | Phase I | Enzalutamide Dexamethasone | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | Terminated | USA | 0 |
NCT06208150 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Talquetamab-tgvs + Teclistamab Pomalidomide + Talquetamab-tgvs Dexamethasone | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT00549848 | Phase III | Daunorubicin + Pegaspargase + Vincristine Sulfate Cytarabine Mercaptopurine Thioguanine Clofarabine + Cyclophosphamide + Etoposide Methotrexate Dasatinib Doxorubicin Dexamethasone | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT01428492 | Phase I | Afuresertib Bortezomib Dexamethasone | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma | Completed | USA | IRL | CAN | AUS | 1 |
NCT02265510 | Phase I | Gemcitabine Carfilzomib Dexamethasone Lenalidomide Nab-paclitaxel Azacitidine INCB052793 Bortezomib | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | Terminated | USA | 0 |
NCT01729091 | Phase Ib/II | Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide | Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma | Completed | USA | 0 |
NCT02579863 | Phase III | Pembrolizumab Dexamethasone Lenalidomide | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | Terminated | 0 | |
NCT06203912 | Phase I | Cyclophosphamide Dexamethasone Isatuximab + TGF-beta-imprinted NK cells | Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT01256398 | Phase II | Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT02532192 | Phase I | Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat | A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Withdrawn | 0 | |
NCT02211014 | Phase I | Acalabrutinib Dexamethasone | An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma | Completed | USA | GBR | 0 |
NCT02506959 | Phase II | Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma | Completed | USA | 0 |
NCT03020030 | Phase III | Nelarabine Dexrazoxane Asparaginase Vincristine Sulfate Cyclophosphamide Cytarabine Mercaptopurine Pegaspargase Methotrexate Etoposide Doxorubicin Dexamethasone Prednisone Dasatinib Leucovorin | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | Active, not recruiting | USA | CAN | 0 |
NCT02419755 | Phase II | Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | Terminated | USA | 0 |
NCT03117751 | Phase II | Cyclophosphamide Vincristine Sulfate Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Active, not recruiting | USA | AUS | 0 |
NCT02419495 | Phase I | Cyclophosphamide Pemetrexed Disodium Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin | Selinexor in Combination With Standard Chemotherapy | Terminated | USA | 0 |
NCT02553460 | Phase II | Cyclophosphamide Mitoxantrone Dexamethasone Bortezomib Etoposide Vincristine Sulfate Pegaspargase Vorinostat Cytarabine Methotrexate Leucovorin | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | Active, not recruiting | USA | CAN | 0 |
NCT02030483 | Phase I | Palbociclib Dexamethasone Lenalidomide | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma | Terminated | USA | 0 |
NCT01863550 | Phase III | Dexamethasone Lenalidomide Carfilzomib Bortezomib | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 1 |
NCT03411031 | Phase II | Elotuzumab + Lenalidomide Dexamethasone | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | Terminated | USA | 0 |
NCT02589145 | Phase Ib/II | Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | Terminated | USA | 0 |
NCT02352558 | Phase I | Imatinib Napabucasin Bortezomib Ibrutinib Dexamethasone | A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT01846611 | Phase III | Pegylated liposomal doxorubicin Dexamethasone | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | POL | NZL | ISR | GBR | CHE | AUS | 3 |
NCT03007147 | Phase III | Pegaspargase Methotrexate Leucovorin Cytarabine Mercaptopurine Thioguanine Vincristine Sulfate Cyclophosphamide Imatinib Ifosfamide Dexrazoxane Daunorubicin Dexamethasone Methylprednisolone Etoposide Prednisolone Doxorubicin | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Active, not recruiting | USA | SWE | NZL | NLD | ITA | ISR | FRA | FIN | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 4 |
NCT05848687 | Phase Ib/II | Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Recruiting | USA | CAN | 0 |
NCT03860844 | Phase II | Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Sulfate Pegaspargase | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | Terminated | USA | SWE | NOR | NLD | ITA | HUN | GRC | FRA | DNK | DEU | BRA | ARG | 4 |
NCT01983969 | Phase Ib/II | Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + Vorinostat | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | Completed | USA | 0 |
NCT02427620 | Phase II | Cyclophosphamide + Doxorubicin + Vincristine Sulfate Filgrastim Dexamethasone Cytarabine + Methotrexate Leucovorin | A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT06232707 | Phase III | Carfilzomib Pomalidomide Elotuzumab Dexamethasone Daratumumab CC-93269 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE) | Withdrawn | USA | TUR | SWE | ROU | NOR | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT04524455 | Phase I | Dexamethasone AMG 404 + Blinatumomab | A Study of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Acute Lymphoblastic Leukemia (ALL) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUT | AUS | 0 |
NCT02112916 | Phase III | Cyclophosphamide Vincristine Sulfate Ifosfamide Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Leucovorin Daunorubicin Dexamethasone Bortezomib Etoposide Doxorubicin | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | Active, not recruiting | USA | NZL | CAN | AUS | 0 |
NCT02616640 | Phase I | Pomalidomide Dexamethasone Durvalumab | A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
NCT06216158 | Phase III | Iberdomide Iberdomide + Isatuximab Dexamethasone | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | Recruiting | DEU | 0 |
NCT01962792 | Phase Ib/II | Carfilzomib + Ibrutinib Dexamethasone | Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | Completed | USA | CAN | 0 |
NCT01319981 | Phase II | Pegfilgrastim Imatinib Filgrastim Rituximab Doxorubicin Dexamethasone Vincristine Sulfate Cyclophosphamide | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT03626922 | Phase I | Folic Acid Cyanocobalamin Oxaliplatin + Pembrolizumab + Pemetrexed Disodium Dexamethasone Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | Unknown status | USA | 0 |